Clinical significance of inflammatory burden index in predicting prognosis of patients with mixed hepatocellular carcinoma and cholangiocarcinoma
Objective To investigate the clinical significance of inflammatory burden index(IBI)in predicting prognosis of patients with combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma(cHCC-CCA).Methods A retrospective data was conducted on a total of 106 patients diagnosed with cHCC-CCA after undergoing therapeutic liver resection in our hospital from January 2019 to February 2023.Based on the preoperative whole blood count,the systemic inflammatory index,including neutrophil to lymphocyte ratio(NLR),platelet to lymphocyte ratio(PLR),monocyte to lymphocyte ratio(mlR),inflammatory burden index(IBI),and systemic immune inflammatory index(SII)were calculated.Overall survival(OS),and disease-free survival(DFS)was followed-up.Results Among the five inflammatory biomarker combination parameters,the C statistic of IBI in predicting the risk of death in cHCC-CCA patients was 0.822(95%CI:0.731-0.912),which was significantly higher than other indicators(P<0.05).All cHCC-CCA patients were divided into low IBI group(<101.03)and high IBI group(≥101.03)according to the IBI cutoff value.IBI values in cHCC-CCA patients were associated with higher T stage and AJCC stage and lower histological differentiation(P<0.05).The median DFS and OS of high IBI group was 16 months and 24 months,which was shorter than that of low IBI group(54 months and 40 months),and the differences were statistically significant(P<0.05).Univariate and multivariate Cox regression analysis showed that high IBI was one of the independent risk factors for postoperative death and recurrence of cHCC-CCA(P<0.05).Conclusion IBI could be a powerful prognostic factor for cHCC CCA and can serve as a useful tool in prognostic assessment.
NETL
NSTL
万方数据
